Opevesostat

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Prostate CancerMalignant Neoplasm

1399 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

1

Mekinist

Novartis

Preclinical

32

Opevesostat

Merck & Co.

Phase 2

43

Jatenzo

GGrupo Espanol de Tumores Neuroendocrinos

Preclinical

24

Viagra

VViatris Specialty LLC

Preclinical

15

Duragesic

CCephalon

Preclinical

16

Ranexa

MMenarini International Operations Luxembourg SA

Preclinical

17

Prednisone/prednisolone

Roche

Preclinical

38

Triptorelin Pamoate

Ipsen

Preclinical

29

Xylocaine

MMEDRx USA, Inc.

Preclinical

—10

Naropin

FFresenius Kabi Oncology Ltd.

Preclinical

—Show 12 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Prostate Cancer4 trials

A Study of Opevesostat (MK-568)4 in Japanese Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-005)

Active, not recruiting·Merck & Co.·Phase 1·NCT06104449·6 enrolled

A Study of Opevesostat (MK-5684) in China Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (MK-5684-001)

Completed·Merck & Co.·Phase 1·NCT06136598·14 enrolled

Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)

Recruiting·Merck & Co.·Phase 1/2·NCT06353386·220 enrolled

Show 1 more trial

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

Recruiting·Merck & Co.·Phase 3·NCT06136650·1,314 enrolled

Absorption1 trial

A Study of the Absorption, Distribution, Metabolism, and Elimination of Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-008)

Completed·Merck & Co.·Phase 1·NCT06566989·8 enrolled

mCRPC1 trial

Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

Recruiting·Merck & Co.·Phase 3·NCT06136624·1,310 enrolled

Moderate Hepatic Impairment1 trial

A Study to Evaluate Opevesostat (MK-5684) in Male Participants With Moderate Hepatic Impairment (MK-5684-009)

Completed·Merck & Co.·Phase 1·NCT06860243·16 enrolled

Interaction1 trial

A Drug-Drug Interaction Study of Carbamazepine and Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-012)

Completed·Merck & Co.·Phase 1·NCT06633419·14 enrolled

2 more indications

Malignant Neoplasm1 trial

A Multicenter, Open-label, Phase 2 Basket Study of MK-5684 in Participants With Selected Solid Tumors (OMAHA-015)

Recruiting·Merck & Co.·Phase 2·NCT06979596·250 enrolled

Unspecified1 trial

A Phase 1, Open-Label, Fixed-Sequence Study to Evaluate the Effects of Multiple Doses of Itraconazole on the Single-Dose Pharmacokinetics of MK-5684 in Healthy Adult Male Participants

Completed·Merck & Co.·Phase 1·NCT07548606·14 enrolled

Details

Drug Info

Related News